Article

Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma. A systematic review and network meta-analysis.

Reza ELAIDI, PhD [1*]; Letuan PHAN, MSc [1*]; Delphine BORCHIELLINI, MD PhD[2]; Philippe BARTHELEMY, MD PhD[3]; Alain RAVAUD, MD PhD[4]; Stéphane OUDARD and MD PhD [5]; Yann VANO MD PhD[5].



Figure S1. - Forest plot for direct comparisons in the ITT population (A) and per IMDC subgroup (B). (Online only).



Figure S2. – Forest plot from the random effect model in the ITT population (Online only). Forest plot of the indirect comparison between each combination for the 3 outcomes in the ITT population with random effect model using informative priors. We took empirical priors for the between-study variance (heterogeneity) as proposed by R.Turner (2015). Other priors have also been tested as sensibility analysis but since very few information are available for the combination, more data are needed to build more reliable informative priors.



Figure S3. - Forest plot with added Atezo + Beva combination in the ITT population (Online only).

Table S1. –Bias assessment risk for the 3 selected studies of the network (Online only).

	Checkmate 214	**Keynote 426**	**Javelin Renal 101**
Random sequence generation	Low	Low	Low
Allocation concealment	Low	Low	Low
Blinding of participants and personnel	High	High	High
Blinding (outcome assessment)	Unclear	Low	Low
Incomplete outcome data	Low	Low	Unclear
Selective reporting	Low	Low	Low
Other sources of bias	Low	Low	Low

Table S2. – Sources of all data extracted (Online only).

	Trial	**Outcome**	**Source**
ITT	**Checkmate 214**	PFS	Article – The Lancet
		OS	Article – The Lancet
		ORR	Article – The Lancet
	Keynote 426	PFS	Article – New England Journal of Medicine

		OS	Article – New England Journal of Medicine
		ORR	Article – New England Journal of Medicine
	Javelin renal 101	PFS	Presentation at ASCO GU
		OS	Article – New England Journal of Medicine
		ORR	Presentation at ASCO GU
	IMmotion 151	PFS	Article – The Lancet
		OS	Article – The Lancet
		ORR	Article – The Lancet
IMDC subgroups	**Checkmate 214**	PFS	Article – The Lancet
		ORR	Article – The Lancet
	Keynote 426	PFS	Presentation at ASCO
		ORR	Presentation at ASCO
	Javelin renal 101	PFS	Presentation at ASCO GU
		ORR	Presentation at ASCO GU
	CABOSUN	PFS	Article – European Journal of Cancer
		ORR	Article – European Journal of Cancer

Table S3. - Ranking from PFS, OS and ORR in the ITT population – contrast-based approach (Online only).

Progression-free survival					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.011	0.089	**0.884**	0.017	37%
Pembro + Axi	0.466	**0.480**	0.053	0.000	80%
Ave + Axi	**0.523**	0.431	0.046	0.000	83%
Sunitinib	0.000	0.000	0.017	**0.983**	1%
Random effect model					
Nivo + Ipi	0.132	0.2	0.468	0.171	42%
Pembro + Axi	0.411	0.362	0.146	0.081	70%
Ave + Axi	0.447	0.340	0.140	0.073	72%
Sunitinib	0.010	0.069	0.247	0.675	14%
Overall survival					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.058	0.613	0.329	0.000	58%
Pembro + Axi	0.892	0.085	0.023	0.000	96%
Ave + Axi	0.050	0.302	0.584	0.064	45%
Sunitinib	0.000	0.000	0.064	0.936	2%
Random effect model					
Nivo + Ipi	0.122	0.527	0.306	0.045	58%
Pembro + Axi	0.784	0.155	0.052	0.010	90%
Ave + Axi	0.094	0.299	0.459	0.148	45%
Sunitinib	0.000	0.019	0.183	0.797	7%
Objective response rate					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.000	0.000	0.993	0.007	33%
Pembro + Axi	0.174	0.826	0.000	0.000	73%
Ave + Axi	0.826	0.174	0.000	0.000	94%
Sunitinib	0.000	0.000	0.007	0.993	2%
Random effect model					
Nivo + Ipi	0.028	0.073	0.767	0.132	58%
Pembro + Axi	0.286	0.641	0.055	0.018	73%
Ave + Axi	0.684	0.272	0.033	0.010	88%
Sunitinib	0.002	0.013	0.145	0.840	6%

Table S3. - Ranking from PFS and ORR - contrast-based approach (Online only).

Progression-free survival

IMDC good prognosis population					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.001	0.025	0.096	0.878	5%
Pembro + Axi	0.125	0.703	0.124	0.048	63%
Ave + Axi	0.873	0.117	0.008	0.003	95%
Sunitinib	0.002	0.155	0.772	0.071	36%
Random effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.039	0.100	0.176	0.685	16%
Pembro + Axi	0.193	0.520	0.166	0.121	60%
Ave + Axi	0.752	0.174	0.042	0.032	88%
Sunitinib	0.016	0.206	0.616	0.162	36%
Nivo + Ipi	0.001	0.025	0.096	0.878	5%
IMDC intermediate/poor prognosis population					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.087	0.310	0.602	0.001	49%
Pembro + Axi	0.553	0.329	0.118	0.000	81%
Ave + Axi	0.360	0.361	0.270	0.009	69%
Sunitinib	0.000	0.000	0.010	0.990	3%
Random effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.188	0.311	0.379	0.121	52%
Pembro + Axi	0.459	0.304	0.167	0.069	72%
Ave + Axi	0.344	0.325	0.234	0.097	64%
Sunitinib	0.009	0.059	0.220	0.712	12%
Objective response rate					
IMDC good prognosis population					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.000	0.001	0.040	0.96	1%
Pembro + Axi	0.076	0.923	0.002	0.00	69%
Ave + Axi	0.924	0.076	0.000	0.00	97%
Sunitinib	0.000	0.001	0.959	0.04	32%
Random effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.062	0.116	0.170	0.653	20%
Pembro + Axi	0.272	0.475	0.135	0.119	63%
Ave + Axi	0.645	0.226	0.080	0.049	82%
Sunitinib	0.021	0.184	0.616	0.179	35%
IMDC intermediate/poor prognosis population					
Fixed effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.005	0.295	0.700	0	44%
Pembro + Axi	0.040	0.661	0.299	0	58%
Ave + Axi	0.955	0.044	0.001	0	98%
Sunitinib	0.000	0.000	0.000	1	0%
Random effect model	**Rank 1**	**Rank 2**	**Rank 3**	**Rank 4**	**SUCRA**
Nivo + Ipi	0.198	0.293	0.322	0.187	50%
Pembro + Axi	0.249	0.341	0.246	0.164	56%
Ave + Axi	0.541	0.257	0.120	0.082	75%
Sunitinib	0.012	0.110	0.311	0.567	19%

Table S4. - Parameter estimation of the arm-based Weibull model for progression-free survival and overall survival (Online only).

Study	Parameter	Estimation	SD	95% CrI CrI upper
Progression-free survival				
Checkmate 214 Nivo+Ipi	Delta1	0.2343	0.1018	[-0.422; -0.0177]
	Delta2	-0.094	0.1074	[-0.314; 0.110]
	Mu1	-2.248	0.0825	[-2.415; -2.091]
	Mu2	-0.4521	0.0902	[-0.6281; -0.275]

Keynote 426 Pembro+Axi	Delta1	-0.2866	0.0996	[-0.494; -0.101]
	Delta2	-0.0563	0.1166	[-0.270; 0.189]
	Mu1	-2.752	0.0878	[-2.925 ; -2.581]
	Mu2	-0.0140	0.1265	[-0.264 ; 0.232]
Javelin Renal 101 Ave+Axi	Delta1	-0.2888	0.101	[-0.498; -0.0996]
	Delta2	-0.071	0.1049	[-0.272 ; 0.140]
	Mu1	-2.336	0.0916	[-2.517 ; -2.158]
	Mu2	-0.241	0.09381	[-0.426 ; -0.058]
Overall survival				
Checkmate 214 Nivo+Ipi	Delta1	-0.424	0.159	[-0.730 ; -0.108]
	Delta2	0.076	0.107	[-0.137 ; 0.282]
	Mu1	-4.001	0.129	[-4.257 ; -3.752]
	Mu2	0.056	0.083	[-0.108 ; 0.220]
Keynote 426 Pembro+Axi	Delta1	0.076	0.107	[-0.137 ; 0.282]
	Delta2	-0.462	0.162	[-0.787 ; -0.150]
	Mu1	-4.112	0.153	[-4.421 ; -3.821]
	Mu2	0.068	0.177	[-0.277 ; 0.411]
Javelin Renal 101 Ave+Axi	Delta1	0.077	0.130	[-0.175 ; 0.334]
	Delta2	-0.429	0.164	[-0.748 ; -0.106]
	Mu1	-4.170	0.182	[-4.537 ; -3.824]
	Mu2	0.183	0.133	[-0.078 ; 0.443]

Note: Delta 1 and Delta 2 refer to the experimental arm Weibull parameters, as described by Ouwen and Jansen. Mu 1 and Mu 2 refer to the control arm Weibull parameters, as described by Ouwen and Jansen.

Detailed search strategy for systematic review (Online only)

Research question: Comparing the efficacy of the new treatment combinations for patients with metastatic renal cell carcinoma in the first-line setting, in term of progression-free survival, overall survival and objective response rate.

Eligibility criteria

Inclusion criteria:

Randomized controlled trial
Include patients with metastatic renal cell carcinoma
Experimental treatment involves immune checkpoint inhibitor combination

Exclusion criteria:

Not reporting the co-primary outcomes
Include only subpopulation (i.e. age or region restraint, IMDC subgroups …etc.)
Include patients previously treated for renal cell carcinoma (not in first-line setting)

Searched databases:

Pubmed, Cochrane library, Clinicaltrial.gov, relevant congresses (ESMO, ASCO, ….etc)

Keyword:

"renal cell carcinoma" AND (randomized controlled trial)

Details in PubMed:

"renal cell carcinoma"[All Fields] AND ("randomized controlled trial"[Publication Type] OR "randomized controlled trials as topic"[MeSH Terms] OR "randomized controlled trial"[All Fields] OR "randomised controlled trial"[All Fields]) AND ("2015/01/01"[PDAT] : "2019/10/31"[PDAT])

Cochrane Library:

(randomized clinical trial "renal cell carcinoma" metastatic or advanced "Immune checkpoint inhibitor"):ti,ab,kw with Publication Year from 2015 to 2019, with Cochrane Library publication date Between Jan 2015 and Oct 2019, in Trials (Word variations have been searched) 603

(See flowchart for election process)